Collaboration in Small Molecule Drug Discovery
858 Therapeutics and OpenBench have joined forces to undertake a significant collaboration focused on the discovery of small molecule inhibitors. This partnership aims to harness OpenBench’s advanced structure-based machine learning platform, enhancing the drug discovery process. The initial phase of this collaboration will concentrate on a target that remains undisclosed but is nominated by 858 Therapeutics.
Terms of the Agreement
According to the agreement, both companies will work together to navigate through the drug discovery landscape, particularly up to hit validation. OpenBench is tasked with the identification of new and potentially developable chemical series. Once these series are discovered, 858 Therapeutics will conduct characterization and validation through their proprietary biochemical, biophysical, and cellular assays. Notably, OpenBench has the opportunity to earn milestone payments based on the success of novel chemotypes that align with specific molecular properties outlined by 858 Therapeutics. As part of the collaboration, 858 will gain complete and exclusive rights to any acquired chemotypes and be solely accountable for their future research and development. While comprehensive financial details of this agreement remain undisclosed, it signifies a substantial commitment from both parties.
Leadership Insight
Expressing enthusiasm for the new venture, Jeffrey Stafford, Ph.D., the CEO of 858 Therapeutics, emphasized the exciting nature of the collaboration, stating, “We are excited to launch this collaboration with OpenBench. Through its proprietary AI platform, the OpenBench team has built a track record of identifying novel, tractable chemical matter against challenging targets.” His perspective showcases a forward-thinking vision aimed at creating innovative therapies.
OpenBench's Perspective
Lewis Martin, Ph.D., the Chief Scientific Officer of OpenBench, echoed similar sentiments, highlighting the distinctive strengths of 858 Therapeutics. He mentioned, “858 has an innovative pipeline borne of deep biological insight into novel targets. We are thrilled to apply our specialized discovery approach to enrich their vision of bringing new therapies to patients.” This outlook contributes to a robust and synergistic partnership geared towards tackling pressing medical challenges.
About 858 Therapeutics
Located in the vibrant biotech hub, 858 Therapeutics focuses on developing a range of small molecule therapeutics that target novel oncology and immunology aspects. Their primary initiatives revolve around key areas of cancer biology, emphasizing critical nodes such as DNA damage repair, innate immunity, and RNA epigenetics. With a strong pipeline and a commitment to innovation, 858 Therapeutics stands at the forefront of biotechnological advancements.
About OpenBench
OpenBench is transcending traditional drug discovery methodologies by fostering success-driven collaborations. This pioneering model aims to bolster early discovery processes through AI integration, allowing for effective virtual screening, custom synthesis, and experimental validation while ensuring every dollar spent is directed towards identifying potent, developable hits. Their proprietary structure-based machine learning platform has proven successful in locating quality, progressible chemical matters for over 90% of targets addressed thus far, indicating robust efficacy in their approach.
Frequently Asked Questions
What is the focus of the collaboration between 858 Therapeutics and OpenBench?
The collaboration primarily aims to discover small molecule inhibitors using OpenBench's advanced structure-based machine learning platform, focusing on an undisclosed target nominated by 858 Therapeutics.
How will success be measured in this collaboration?
Success will be gauged via hit validation and milestone payments for novel chemotypes that adhere to specific molecular properties laid out by 858 Therapeutics.
What are the key areas of focus for 858 Therapeutics?
858 Therapeutics centers its efforts on small molecule therapeutics targeting notable sectors of oncology and immunology, including DNA damage repair and RNA epigenetics.
What unique methodologies does OpenBench implement in drug discovery?
OpenBench employs a success-driven collaboration model that leverages AI, ensuring costs are effectively used for developing potent, viable hits from the beginning of the partnership.
Is there any financial information available regarding the collaboration?
While detailed financial terms were not disclosed, it is indicated that OpenBench may receive milestone payments based on the success of the chemical series identified.
